Microcap Ledger Lantern Pharma Inc. $LTRN
Facts as of . Built from SEC filings and our own data. Small caps move fast; check the latest filings.
Snapshot
- Exchange
- Nasdaq Capital Market
- Sector
- Pharmaceutical Preparations
- Headquarters
- Dallas, TX
- Fiscal year end
- December 31
- Shares outstanding
- 12,784,146 [10-Q 2026-08-14]
What the company doesAI summary of filing
Lantern Pharma Inc. is a clinical-stage biopharmaceutical company developing cancer therapies using its proprietary RADR artificial intelligence platform. The company's pipeline includes three clinical-stage small molecule drug candidates (LP-300, LP-184, and LP-284), an antibody-drug conjugate program in preclinical development, and an additional candidate (LP-100). Lantern generates no product revenue but plans to commercialize AI platform modules and services starting in 2026, while currently deriving limited revenue from research grants. The company employs a dual strategy of developing new compounds and rescuing previously abandoned drug candidates by applying AI-driven biomarker analysis to identify specific patient populations likely to respond to treatment. [10-K 2026-03-30]
Financial health
| Period | Revenue | Net income | Operating cash flow | Cash | Filing |
|---|---|---|---|---|---|
| 6 months to Jun 2026 | — | −$10.40M | −$6.71M | $6.66M | [10-Q 2026-08-14] |
| FY ended Dec 2025 | — | −$17.12M | −$15.68M | $4.42M | [PRE 14A 2026-10-08] |
| FY ended Dec 2024 | — | −$20.78M | −$17.81M | $7.51M | [PRE 14A 2026-10-08] |
- Quarterly cash burn
- −$3.36M
- Cash runway Estimate
- ~6 months
Capital structure and dilution
| Date | Shares outstanding | Filing |
|---|---|---|
| 2025-04-28 | 10,784,725 | [10-K/A 2025-04-30] |
| 2025-05-09 | 10,784,725 | [10-Q 2025-05-15] |
| 2025-08-08 | 10,799,417 | [10-Q 2025-08-13] |
| 2025-11-05 | 11,184,423 | [10-Q 2025-11-12] |
| 2026-03-13 | 11,254,697 | [10-K 2026-03-30] |
| 2026-04-29 | 11,304,697 | [10-K/A 2026-04-30] |
| 2026-05-12 | 11,304,697 | [10-Q 2026-05-15] |
| 2026-08-10 | 12,784,146 | [10-Q 2026-08-14] |
- Shelf registration
- S-1 filed 2026-06-12; declared effective 2026-06-18 [S-1 2026-06-12]
Listing status
Current status: 1 Form 8-K Item 3.01 filing(s) in the last 24 months, most recent 2026-10-01. Item 3.01 covers delisting notices, failures to meet a listing rule and listing transfers; read the filing for which one.
| Date | Event | Details | Deadline | Filing |
|---|---|---|---|---|
| 2026-10-01 | 8-K Item 3.01 | Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing | — | [8-K 2026-10-01] |
Who owns it
| Date | Insider | Type | Shares | Price | Filing |
|---|---|---|---|---|---|
| 2026-05-12 | Schalop Lee Troy | buy | 48,544 | $2.06 | [4 2026-05-14] |
| 2026-05-12 | Keyser D Jeffrey | buy | 48,544 | $2.06 | [4 2026-05-14] |
Catalysts and calendar
| Date | Type | Title |
|---|---|---|
| 2026-10-08 | PRE 14A | Proxy statement |
| 2026-10-01 | 8-K | Listing notice or transfer |
| 2026-09-30 | 8-K | Material agreement entered; Unregistered sale of equity |
| 2026-09-30 | 424B5 | Prospectus or prospectus supplement |
| 2026-09-24 | 8-K | Regulation FD disclosure |
| 2026-09-23 | 8-K | Regulation FD disclosure |
| 2026-08-14 | 8-K | Results of operations; Regulation FD disclosure |
| 2026-08-14 | 10-Q | Quarterly report |
| 2026-08-04 | 13G | Beneficial ownership report (5%+ holder) |
| 2026-08-03 | 8-K | Regulation FD disclosure |
| 2026-07-23 | 13G/A | Beneficial ownership report (5%+ holder) |
| 2026-06-12 | S-1 | Registration statement |
Alerts for $LTRN
Email me when Lantern Pharma Inc. files an offering, gets a deficiency notice, or moves sharply.
Facts as of . Small caps move fast; check the latest filings.